# Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

> **NCT01906866** · PHASE3 · COMPLETED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 125 (actual)

## Conditions studied

- Sleep Disorders

## Interventions

- **DRUG:** Circadin 2/5/10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01906866
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2018-03-27
- **Final completion:** 2018-03-27
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01906866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01906866, "Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01906866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*